Biotechnology
Dr. Andreas Wallnöfer Named to Optigo Biotherapeutics Board of Directors
Andreas Wallnöfer; Optigo Biotherapeutics; Board of Directors; ophthalmology; biotechnology; retinal diseases; IND-enabling studies; Hyaluronic Acid anchoring platform; pharmaceutical R&D; drug development
Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors
Life Biosciences; David Guyer; Board of Directors; biotechnology; cellular rejuvenation; epigenetic reprogramming; ER-100; aging; drug development
Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs
Regeneron; ModeX Therapeutics; multispecific antibodies; MSTAR platform; biotechnology deal; upfront payment; milestone payments; immunology; oncology; metabolic diseases; collaboration; OPKO Health
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
Diorasis Therapeutics; Dimitri Azar; Board of Directors; gene therapy; glaucoma; ophthalmology; biotechnology; FDA; clinical development
Connecticut Biotech Veradermics Secures $150M for Phase 3 Trials of Oral Rogaine
Veradermics; Connecticut biotech; oral Rogaine; Phase 3 clinical trials; fundraising; hair loss treatment; biotechnology; clinical development
Ansa Biotechnologies Raises $54.4M in Series B to Scale US DNA Synthesis Manufacturing
Ansa Biotechnologies; Series B financing; DNA synthesis; Cerberus Ventures; US manufacturing; biotechnology; synthetic DNA; fundraising
Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Major Restructuring
Novo Nordisk; Heartseed; heart failure; cell therapy; HS-001; collaboration termination; strategic restructuring; Maziar Mike Doustdar; diabetes; obesity; biotechnology
Lila Sciences Raises $235M to Expand AI Science Factories
Lila Sciences; AI Science Factories; Autonomous Research; Biotechnology; Series A Funding
Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances
Epigenic Therapeutics; NRG Therapeutics; Series B funding; epigenetic therapy; hepatitis B; hypercholesterolemia; Parkinson’s disease; ALS; biotechnology investment; gene silencing
Amgen to Invest Over $600M in New Innovation Centre at California Headquarters
Amgen; innovation centre; science and innovation hub; Thousand Oaks; California; biotechnology; construction; automation; digital tools; therapeutic development; tax incentives; capital investment